DK2125850T3 - MACROCYCLIC POLYMORPHS, COMPOSITIONS INCLUDING SUCH POLYMORPHS, PROCEDURES FOR PREPARING AND USING THEREOF - Google Patents

MACROCYCLIC POLYMORPHS, COMPOSITIONS INCLUDING SUCH POLYMORPHS, PROCEDURES FOR PREPARING AND USING THEREOF Download PDF

Info

Publication number
DK2125850T3
DK2125850T3 DK08713185.0T DK08713185T DK2125850T3 DK 2125850 T3 DK2125850 T3 DK 2125850T3 DK 08713185 T DK08713185 T DK 08713185T DK 2125850 T3 DK2125850 T3 DK 2125850T3
Authority
DK
Denmark
Prior art keywords
compound
polymorph
pharmaceutical composition
formula
mixture
Prior art date
Application number
DK08713185.0T
Other languages
Danish (da)
English (en)
Inventor
Yu-Hung Chiu
Alex Romero
Youe-Kong Shue
Tessie Mary Che
Yoshi Ichikawa
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38661942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2125850(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2125850T3 publication Critical patent/DK2125850T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK08713185.0T 2007-01-22 2008-01-22 MACROCYCLIC POLYMORPHS, COMPOSITIONS INCLUDING SUCH POLYMORPHS, PROCEDURES FOR PREPARING AND USING THEREOF DK2125850T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88195007P 2007-01-22 2007-01-22
US11/831,886 US7378508B2 (en) 2007-01-22 2007-07-31 Polymorphic crystalline forms of tiacumicin B
PCT/US2008/000735 WO2008091554A1 (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Publications (1)

Publication Number Publication Date
DK2125850T3 true DK2125850T3 (en) 2018-07-30

Family

ID=38661942

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08713185.0T DK2125850T3 (en) 2007-01-22 2008-01-22 MACROCYCLIC POLYMORPHS, COMPOSITIONS INCLUDING SUCH POLYMORPHS, PROCEDURES FOR PREPARING AND USING THEREOF

Country Status (23)

Country Link
US (5) US7378508B2 (enExample)
EP (3) EP2468761A1 (enExample)
JP (2) JP5468388B2 (enExample)
KR (2) KR20150006082A (enExample)
CN (2) CN102746353A (enExample)
BR (1) BRPI0806878A2 (enExample)
CA (2) CA2880860A1 (enExample)
CY (1) CY1120358T1 (enExample)
DK (1) DK2125850T3 (enExample)
ES (2) ES2821384T3 (enExample)
HR (1) HRP20180912T1 (enExample)
HU (2) HUE039395T2 (enExample)
IL (2) IL199984A0 (enExample)
LT (1) LT2125850T (enExample)
MX (2) MX348083B (enExample)
NZ (2) NZ601347A (enExample)
PL (2) PL3412678T3 (enExample)
PT (2) PT2125850T (enExample)
RU (1) RU2478643C2 (enExample)
SI (1) SI2125850T1 (enExample)
TR (1) TR201810589T4 (enExample)
TW (2) TWI425942B (enExample)
WO (1) WO2008091554A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113978B2 (ja) * 2003-11-21 2013-01-09 味の素株式会社 グルタミン酸誘導体の有機アミン塩及びその利用
PL2070530T3 (pl) * 2004-05-14 2016-06-30 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7935377B2 (en) * 2004-06-04 2011-05-03 Ajinomoto Co., Inc. Crystals of free (2R, 4R)-monatin and use thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
US9120815B2 (en) 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
CA2799531A1 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Treating recurring clostridium difficile infection using fidaxomicin
US20140024609A1 (en) * 2011-02-04 2014-01-23 Optimer Pharmaceuticals ,Inc. Treatment of Bacterial Infections
US20150157653A1 (en) * 2012-03-16 2015-06-11 Optimer Pharmaceuticals, Inc. Prevention of Clostridium Difficile Infection in High Risk Patients
US8722863B2 (en) 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
EP2855499A1 (en) * 2012-05-10 2015-04-08 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
WO2014135891A1 (en) 2013-03-08 2014-09-12 Cipla Limited Pharmaceutical compositions for rectal administration
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104560766B (zh) * 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
US9862740B2 (en) 2014-02-25 2018-01-09 Olon S.P.A. Process for preparing novel forms of tiacumicin B
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
DK3119793T3 (en) * 2014-03-18 2018-05-22 Xellia Pharmaceuticals Aps NEW POLYMORPHS AND NEW SOLID STATES OF TIACUMICIN B
DK3139932T3 (en) 2014-05-09 2018-11-12 Astellas Pharma Europe Ltd The treatment regimen for thiacumicin compound
WO2015175695A1 (en) * 2014-05-13 2015-11-19 Debrabander Jef Small molecule compounds selective against gram-negative bacterial infections
CN104098637B (zh) * 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
EA034885B1 (ru) 2015-07-03 2020-04-02 Астеллас Фарма Юэроп Лтд. Новая схема лечения тиакумициновым соединением
CN112190589A (zh) * 2020-11-17 2021-01-08 首都医科大学附属北京胸科医院 非达霉素在制备抑制鸟分枝杆菌活性的产品中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4321362A (en) * 1980-06-12 1982-03-23 Eli Lilly And Company De(mycinosyloxy)tylosin and process for its production
US4918174A (en) * 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
ATE309369T1 (de) 2000-04-28 2005-11-15 Kosan Biosciences Inc Heterologe herstellung von polyketiden
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
WO2004014295A2 (en) * 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
WO2006085838A1 (en) * 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
PL2070530T3 (pl) 2004-05-14 2016-06-30 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
EP1940417A4 (en) 2005-10-21 2010-07-07 Optimer Pharmaceuticals Inc METHOD FOR TREATING DIARRHOE IN CONNECTION WITH CLOSTRIDIUM DIFFICILE
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
CN101663312B (zh) 2013-10-23
US7378508B2 (en) 2008-05-27
CA2880860A1 (en) 2008-07-31
TWI453015B (zh) 2014-09-21
CY1120358T1 (el) 2019-07-10
EP2125850A1 (en) 2009-12-02
IL220255A0 (en) 2012-07-31
US20090163428A1 (en) 2009-06-25
NZ601347A (en) 2013-11-29
WO2008091554A1 (en) 2008-07-31
CA2676061A1 (en) 2008-07-31
US20130252914A1 (en) 2013-09-26
MX348083B (es) 2017-05-25
HUE039395T2 (hu) 2018-12-28
ES2821384T3 (es) 2021-04-26
US20080194497A1 (en) 2008-08-14
IL199984A0 (en) 2010-04-15
CN101663312A (zh) 2010-03-03
KR20150006082A (ko) 2015-01-15
US20100081800A1 (en) 2010-04-01
EP3412678B1 (en) 2020-08-19
PL2125850T3 (pl) 2018-08-31
JP2010516681A (ja) 2010-05-20
CN102746353A (zh) 2012-10-24
CA2676061C (en) 2016-01-19
EP2468761A1 (en) 2012-06-27
US20070259949A1 (en) 2007-11-08
SI2125850T1 (en) 2018-08-31
JP5468388B2 (ja) 2014-04-09
AU2008209580A1 (en) 2008-07-31
US8883986B2 (en) 2014-11-11
JP5764168B2 (ja) 2015-08-12
MX2009007730A (es) 2009-08-07
NZ578697A (en) 2012-08-31
TW201350114A (zh) 2013-12-16
BRPI0806878A2 (pt) 2014-06-24
TWI425942B (zh) 2014-02-11
TR201810589T4 (tr) 2018-08-27
JP2013241440A (ja) 2013-12-05
PT3412678T (pt) 2020-09-29
RU2009131727A (ru) 2011-02-27
HRP20180912T1 (hr) 2018-07-27
US8859510B2 (en) 2014-10-14
PT2125850T (pt) 2018-07-11
LT2125850T (lt) 2018-08-10
KR20090117924A (ko) 2009-11-16
EP2125850B1 (en) 2018-05-30
PL3412678T3 (pl) 2020-12-14
US7863249B2 (en) 2011-01-04
HUE052444T2 (hu) 2021-05-28
ES2676308T3 (es) 2018-07-18
RU2478643C2 (ru) 2013-04-10
TW200840562A (en) 2008-10-16
EP3412678A1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
DK2125850T3 (en) MACROCYCLIC POLYMORPHS, COMPOSITIONS INCLUDING SUCH POLYMORPHS, PROCEDURES FOR PREPARING AND USING THEREOF
US8518899B2 (en) Macrocyclic polymorphs, compositions comprising such polymorphs and methods of use and manufacture thereof
AU2011255633B2 (en) Methods of treating recurring bacterial infection
AU2008209580B2 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
AU2012244278B2 (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
HK1134096B (en) Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof
HK1134096A (en) Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof
HK1172627A (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
CN105669798B (zh) 一种大环内酯类化合物